

## **AbbVie Ltd Transparency Disclosure Methodological Notes for Reporting Year 2021**

As a member company of EFPIA and ABPI, AbbVie Ltd is committed to ensure that the nature and scope of transfers of value (ToV) with healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) are clear and transparent to the public. Therefore, AbbVie Ltd has published applicable ToV provided directly or indirectly to HCPs, ORDMs and HCOs for the 2021 calendar year.

This Methodological Note provides guidance on how AbbVie Ltd has recorded and publicly reported this information in accordance with the current editions of ABPI Transparency Code.

### **Reporting period / Reportable ToV:**

The AbbVie Ltd 2021 disclosure includes applicable ToV during the period between 1<sup>st</sup> January 2021 and 31<sup>st</sup> December 2021.

Transactions processed after 14<sup>th</sup> January 2022 will be considered for the next report.

### **Transparency Acknowledgment from HCPs or HCOs:**

Agreements between AbbVie Ltd and HCPs/HCOs relating to ToV may have included a Transparency section where HCPs and HCOs were notified of AbbVie's Transparency disclosure obligations.

### **Consent Approach:**

HCPs have received correspondence explaining AbbVie's commitment to Transparency and the options and rights they have in accordance with the General Data Protection Regulation (GDPR).

AbbVie will publish the total value of the ToV for those HCPs and ORDMs that have provided express consent for such individual disclosure. HCPs and ORDMs not providing consent will have their amounts included in an aggregate amount published per ABPI requirements. Please refer to our Privacy Notice [here](#) for additional information on how AbbVie processes personal data and for a description of the data privacy rights.

If a HCP/ORDM would like to withdraw a consent already provided, they can do so in writing to AbbVie UK Transparency team, emailing [UK.Transparency@abbvie.com](mailto:UK.Transparency@abbvie.com).

### **Partial Consent:**

AbbVie Ltd supports full disclosure. If only partial consent is given by an HCP/ORDM, all the ToV of this HCP/ORDM will be disclosed in aggregate.

### **Multiple Licensed HCPs:**


HCPs with licenses authorising them to practice in more than one country, including United Kingdom, may have ToV disclosed in multiple country reports.

### **Non-Duplication:**

Whenever possible, ToV are disclosed to the respective HCPs. If ToV is provided to the company of an HCP, the ToV will be attributed to the company.

**HCO Disclosure:**

Where it has not been possible to identify an individual hospital or department within an organisation, the HCO will be reported at the highest organisational level as displayed in the below example:



**HCP/HCO Number of Recipients Reported at an Aggregate Level:**

Each category of ToV reported at an aggregate level includes the number of HCPs/HCOs provided with a ToV. Each HCP/HCO that received a ToV is counted as one recipient in each category.

**Cross Border Interactions:**

Reportable ToV provided by AbbVie affiliates (worldwide) to UK HCPs/HCOs have been included.

**Sponsorship Payments made to more than one HCO:**

In the case of sponsorship agreements where different HCOs have participated, it was assumed that each HCO received an equal share and was published for each HCO.

**Pre-Disclosure:**

HCPs and ODRMs that granted consent to disclose on an individual level were contacted during February 2022. They received correspondence containing the details of ToV to be reported according to ABPI requirements. AbbVie Ltd.’s intention was to provide an opportunity for HCPs and ORDM to verify and review the information to ensure it is accurate, prior to ABPI disclosure on 30<sup>th</sup> June 2022.

**ToV Definitions:**

HCPs and ODRM ToV Definition:

- Fee for Service and Consultancy
  - Speaker fee (including associated preparation work and post work)
  - Advisory Boards and other consultancy engagements (including associated preparation work and post work)
  - Chairing a meeting
  - Assistance with Training
  - Educational/Scientific Events

Note: Where AbbVie Ltd knows the identity of a market research participant (single blind market research), the fee(s) will be disclosed under this category.

- Related expenses agreed in the Fee for Service or consultancy contract, such as:
  - Flights
  - Hotel
  - Other transportations costs (mileage, train, taxi, bus, underground, parking)

**Note:** Where incidental expenses are immaterial and unable to be disaggregated from the fees, said expenses will be disclosed under the Fee for Service and Consultancy Fees category.

- Contribution to cost of events e.g., sponsorship for registration fees, travel, and accommodation, such as:
  - Congress/Meeting registration
  - Flights
  - Hotel
  - Other transportations costs (mileage, train, taxi, bus, underground, parking)

#### HCOs ToV Definition:

- Fee for service and consultancy, such as:
  - Speaker fee (including associated preparation work)
  - Advisory Boards and other consultancy engagements (including associated preparation work)
  - Chairing a meeting
  - Training
  - Educational/Scientific Events
- Related expenses agreed in the fee for service or consultancy contract, such as:
  - Flights
  - Hotel
  - Other transportations costs (mileage, train, taxi, bus, underground, parking)
- Contribution to cost of events e.g., sponsorship for registration fees, travel, and accommodation, such as:
  - Congress/Meeting registration
  - Flights
  - Hotel
  - Other transportation costs (mileage, train, taxi, bus, underground, parking)
- Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an event, such as part funded independent education events.
  - When sponsorship also included catering costs and any other forms of funding (e.g., logistical costs) as part of a sponsorship package, these are disclosed as a ToV (sponsorship).
  - Where indirect sponsorship of an HCP occurs through an HCO, the ToV will be disclosed in the name of the recipient HCO.
  - Where a professional conference organiser (PCO) is collaborating with a HCO in the organization of the event, the ToV will be disclosed under the recipient HCO.
  - Where the HCO hasn't been set up as a legal entity, the TOV will be disclosed under the PCO's name with indication of the Specialty Area. Where a PCO is organising an event (via AbbVie provided sponsorship) on behalf of more than one HCO, then the ToV will be disclosed in the name of each recipient HCO.
- Donations, Grants, and benefits in kind to HCOs.

**Date Methodology:**

AbbVie Ltd followed the date methodology when determining which ToV are in scope for current reporting cycle:

- **Event Date** is defined as the date the expense occurred. ToV related to the following categories will use the Event Date when determining applicability for current year reporting requirements (e.g., did the event occur within the reporting period 1<sup>st</sup> January 2021 to 31<sup>st</sup> December 2021).
  - Fee for Service and Consultancy: Expenses
  - Contribution to Cost of Events: Registration Fees
  - Contribution to Cost of Events: Travel and Accommodation
- **Paid Date** is defined as the date the payment was provided to the covered recipient. ToV related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1st January 2021 to 31st December 2021).
  - Fee for Service and Consultancy: Fee
  - Contribution to Cost of Events: Sponsorship Agreements
  - Grants and Donations
  - Research and Development

**Out of Scope:**

Meals, drinks, samples, package deals, promotional aids, and items for patient support (all as defined by Clause 26.3 of the 2021 ABPI Code) are out of scope.

**Value Added Tax (VAT):**

Where applicable, disclosure of payments does not include VAT. Cross border ToV may or may not include VAT depending on the submitting source.

**Social Benefits:**

Where applicable, disclosure of payments does not include Social Benefits.

**Withholding Taxes:**

Where applicable, for services provided in locations outside of United Kingdom, ToV amounts will be reported as in the contract agreement.

**Currency:**

All information is reported in Pound Sterling (GBP).

**Exchange Rate:**

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Ltd Treasury Monthly Average Rates.

**Rounding:**

For each HCP/ODRM/HCO, ToV for each reporting category is rounded to the nearest Pound Sterling (GBP). The Total Amount for each HCP/HCO represents the sum of the reporting category amounts.

**Multiyear Contracts:**

Activities with ToV, crossing calendar years may have the contracted full amount disclosed using the date of last payment.

**Research and Development:**

For the purpose of disclosure, Research and Development (R&D) ToVs are ToVs to HCPs or HCOs related to the planning or conduct of:

- non-clinical studies
- clinical trials
- non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of, individual or groups of HCPs specifically for the study.

The total aggregate disclosure includes ToV made by AbbVie Ltd to HCPs/HCOs, as well as those made by its parent company, subsidiaries, and joint ventures (as required by the partner agreement).

Clinical trials with retrospective elements, including ToV direct or indirect to HCPs/HCOs, have been disclosed at an individual level as a fee for service.

Biological samples and investigational compounds will be excluded from R&D disclosures. These compounds are subject to provisions under the Clinical Trial Directive (their use is submitted in the clinical trial approval process).

Lending of laboratory equipment that is used exclusively for conducting a study and will be returned to AbbVie at the end of the study will not be disclosed in the R&D aggregate amount.

**Post Publication Disputes**

AbbVie will review and investigate disputes with HCPs/HCOs relative to our Transparency reports. Any changes resulting from this review will be published in an updated report.